Chimera Biotec, founded in 2000 as a spin-off from academic research in Germany, has implemented its proprietary DNA-antibody conjugates within the highly innovative Imperacer product line ...
PAT-DX1 targets tumors because it is attracted to and preferentially accumulates near the mass of extracellular DNA released from dead and dying tumor cells. The antibody binds to the DNA ...
Monitoring donor-derived cell-free DNA is a noninvasive means of detecting antibody-mediated rejection of a transplanted kidney. Monitoring donor-derived cell-free DNA (dd-cfDNA) in kidney ...